A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
about
Novel insights into chromosomal conformations in cancer.Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.
P2860
A Phase I Study of Abiraterone Acetate Combined with BEZ235, a Dual PI3K/mTOR Inhibitor, in Metastatic Castration Resistant Prostate Cancer
description
2017 nî lūn-bûn
@nan
2017 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մարտին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
A Phase I Study of Abiraterone ...... tion Resistant Prostate Cancer
@ast
A Phase I Study of Abiraterone ...... tion Resistant Prostate Cancer
@en
type
label
A Phase I Study of Abiraterone ...... tion Resistant Prostate Cancer
@ast
A Phase I Study of Abiraterone ...... tion Resistant Prostate Cancer
@en
prefLabel
A Phase I Study of Abiraterone ...... tion Resistant Prostate Cancer
@ast
A Phase I Study of Abiraterone ...... tion Resistant Prostate Cancer
@en
P2093
P2860
P1433
P1476
A Phase I Study of Abiraterone ...... tion Resistant Prostate Cancer
@en
P2093
Andrew C Hsieh
Charles J Ryan
Mirela Louttit
Terence Friedlander
Xiao X Wei
P2860
P304
P356
10.1634/THEONCOLOGIST.2016-0432
P577
2017-03-17T00:00:00Z